Experimental Vaccine Offers Partial Protection against HIV-Related Virus in Monkeys

alt

An investigational adenovirus prime-poxvirus booster vaccine regimen reduced the likelihood of infection in rhesus monkeys exposed to simian immunodeficiency virus (SIV), a monkey virus similar to HIV, researchers reported in the January 4, 2011, advance online edition of Nature. The vaccine reduced infection risk by about 80% compared with placebo, and monkeys that did become infected had lower viral loads.

Below is an edited excerpt from a press release issued by the National Institute of Allergy and Infectious Diseases (NIAID) describing the study and its findings.

Experimental Vaccine Partially Protects Monkeys from HIV-Like Infection

January 4, 2012 -- New vaccine research in monkeys suggests that scientists are homing in on the critical ingredients of a protective HIV vaccine and identifies new HIV vaccine candidates to test in human clinical trials. The research, which appears online in Natureon Jan. 4, was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

In the study, scientists report that several Simian Immunodeficiency Virus (SIV) prime-boost vaccine regimens have demonstrated partial protection against acquisition of infection by a virulent, tough-to-neutralize SIV strain that is different from the strain used to make the vaccine -- a scenario analogous to what people might encounter if an HIV vaccine were available. The experimental vaccine regimens reduced the monkeys’ likelihood of becoming infected per exposure to SIV by 80 to 83 percent compared to a placebo vaccine regimen. Further, in those monkeys that did become infected, the experimental vaccine regimens substantially reduced the amount of virus in the blood compared to controls. Now plans are underway for early-stage clinical trials of a human-adapted version of one of the study’s prime-boost vaccine combinations.

The best predictor of protection from SIV in the vaccinated monkeys was the presence of antibodies that latched onto the virus surface protein. This finding reinforces what scientists have learned so far about why the first modestly effective HIV vaccine worked in humans and indicates that the HIV surface protein Env is a critical vaccine ingredient. The new research also provides strong evidence that the immune system’s mechanism for preventing infection is significantly different from its mechanism for controlling viral replication.

The research was led by first author Dan Barouch, MD, PhD, of Beth Israel Deaconess Medical Center at Harvard Medical School and the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard. The senior authors of the new paper are Nelson Michael, MD, PhD, of the U.S. Military HIV Research Program (MHRP), and Jaap Goudsmit, MD, PhD, of Crucell Holland BV. NIAID intramural investigators Vanessa Hirsch, SD, DVM, and Ilnour Ourmanov, PhD, collaborated on the research. MHRP and the Ragon Institute co-funded the studies with NIAID.

Investigator affiliations: Division of Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Ragon Institute of MGH, MIT, and Harvard, Boston, MA; Duke University Medical Center, Durham, NC; University of California Irvine School of Medicine, Irvine, CA; National Institute of Allergy and Infectious Diseases, Bethesda, MD; New England Primate Research Center, Southborough, MA; EMMES Corporation, Rockville, MD; Crucell Holland BV, Leiden, Netherlands; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD.

1/10/12

Reference

DH Barouch, J Liu, H Li, et al. Vaccineprotection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. January 4, 2012 (Epub ahead of print).

Other Sources

NIAID. Experimental Vaccine Partially Protects Monkeys from HIV-Like Infection. Press release. January 4, 2012.

Military HIV Research Program. Promising Results of Novel Combination HIV Vaccine. Press release. January 4, 2012.

Ragon Institute. Promising Results Shown in Novel Combination HIV Vaccine. Press release. January 4, 2012.

Crucell N.V. Preclinical Study Provides Strong Rationale for HIV Vaccine Clinical Trials. Press release. January 5, 2012.